FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313550119> ?p ?o ?g. }

• W4313550119 endingPage "e000395" @default.
• W4313550119 startingPage "e000395" @default.
• W4313550119 abstract "Objective To develop a measure for fair inclusion in pivotal trials by assessing transparency and representation of enrolled women, older adults (aged 65 years and older), and racially and ethnically minoritized patients. Design Retrospective cross sectional study. Population Sponsors of novel oncology therapeutics that were approved by the US Food and Drug Administration over 1 January 2012 to 31 December 2017. Data sources Trial data from Drugs@FDA, ClinicalTrials.gov, and corresponding publications; cancer incidence demographics from US Cancer Statistics and the American Cancer Society. Main outcome measures Transparency measures assess whether trials publicly report participant sex, age, and racial and ethnic identity. Representation measures assess whether trial participant demographics represent more than 80% of the US patient population for studied conditions, calculated by dividing the percentage of study participants in each demographic subgroup by the percentage of the US cancer population with the studied condition per group. Composite fair inclusion measures assess average transparency and representation scores, overall and for each demographic group. Results are reported at the trial, product, and sponsor levels. Results Between 1 January 2012 and 31 December 2017, the FDA approved 59 novel cancer therapeutics, submitted by 25 sponsors (all industry companies) on the basis of 64 pivotal trials. All 25 sponsors (100%) reported participant sex, 10 (40%) reported age, and six (24%) reported race and ethnicity. Although 14 (56%) sponsors had adequate representation of women in trials, only six (24%) adequately represented older adults, and four (16%) adequately represented racially and ethnically minoritized patients (black, Asian, Hispanic or Latinx). On overall fair inclusion, one sponsor scored 100% and the median sponsor score was 81% (interquartile range 75-87%). More than half of sponsors (13 (56%) of 25) fairly included women, 20% (n=5) fairly included older adults, and 4% (n=1) fairly included racially and ethnically minoritized patients in trials. 80% of product had pivotal trials that fairly included women, 24% fairly included older adults, and 5% fairly included racially and ethnically minoritized patients. Conclusions This novel approach evaluates trials, products, and sponsors on their fair inclusion of demographic groups in research. For oncology trials, substantial room was noted for improved inclusion of older adults and patients who identify as black or Latinx and transparency around the number of participants identifying as Native Hawaiian, Pacific Islander, American Indian, and Alaska Native. These measures can be used by sponsors, ethics committees, among others, to set and evaluate trial diversity goals to help spur progress toward greater research equity in the US." @default.
• W4313550119 created "2023-01-06" @default.
• W4313550119 creator A5006841844 @default.
• W4313550119 creator A5022298557 @default.
• W4313550119 creator A5031832642 @default.
• W4313550119 creator A5041605241 @default.
• W4313550119 creator A5078289544 @default.
• W4313550119 date "2023-01-01" @default.
• W4313550119 modified "2023-10-06" @default.
• W4313550119 title "Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study" @default.
• W4313550119 cites W134516892 @default.
• W4313550119 cites W1997992200 @default.
• W4313550119 cites W2030703142 @default.
• W4313550119 cites W2054843689 @default.
• W4313550119 cites W2063210326 @default.
• W4313550119 cites W2073944740 @default.
• W4313550119 cites W2074048861 @default.
• W4313550119 cites W2085658053 @default.
• W4313550119 cites W2097771589 @default.
• W4313550119 cites W2149386818 @default.
• W4313550119 cites W2164640826 @default.
• W4313550119 cites W2213629364 @default.
• W4313550119 cites W2337821671 @default.
• W4313550119 cites W2340835891 @default.
• W4313550119 cites W2912408630 @default.
• W4313550119 cites W2948757873 @default.
• W4313550119 cites W2957912263 @default.
• W4313550119 cites W2969031691 @default.
• W4313550119 cites W2981513180 @default.
• W4313550119 cites W3009137536 @default.
• W4313550119 cites W3087595029 @default.
• W4313550119 cites W3112482680 @default.
• W4313550119 cites W3121378041 @default.
• W4313550119 cites W3152697302 @default.
• W4313550119 cites W3155500810 @default.
• W4313550119 cites W3174147445 @default.
• W4313550119 cites W3184431028 @default.
• W4313550119 cites W3199961437 @default.
• W4313550119 cites W3211408107 @default.
• W4313550119 cites W3212901882 @default.
• W4313550119 cites W3214271497 @default.
• W4313550119 cites W4200087172 @default.
• W4313550119 doi "https://doi.org/10.1136/bmjmed-2022-000395" @default.
• W4313550119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36936269" @default.
• W4313550119 hasPublicationYear "2023" @default.
• W4313550119 type Work @default.
• W4313550119 citedByCount "7" @default.
• W4313550119 countsByYear W43135501192023 @default.
• W4313550119 crossrefType "journal-article" @default.
• W4313550119 hasAuthorship W4313550119A5006841844 @default.
• W4313550119 hasAuthorship W4313550119A5022298557 @default.
• W4313550119 hasAuthorship W4313550119A5031832642 @default.
• W4313550119 hasAuthorship W4313550119A5041605241 @default.
• W4313550119 hasAuthorship W4313550119A5078289544 @default.
• W4313550119 hasBestOaLocation W43135501191 @default.
• W4313550119 hasConcept C126322002 @default.
• W4313550119 hasConcept C137403100 @default.
• W4313550119 hasConcept C144024400 @default.
• W4313550119 hasConcept C149923435 @default.
• W4313550119 hasConcept C19165224 @default.
• W4313550119 hasConcept C2780084366 @default.
• W4313550119 hasConcept C2908647359 @default.
• W4313550119 hasConcept C512399662 @default.
• W4313550119 hasConcept C535046627 @default.
• W4313550119 hasConcept C71924100 @default.
• W4313550119 hasConcept C74909509 @default.
• W4313550119 hasConcept C99454951 @default.
• W4313550119 hasConceptScore W4313550119C126322002 @default.
• W4313550119 hasConceptScore W4313550119C137403100 @default.
• W4313550119 hasConceptScore W4313550119C144024400 @default.
• W4313550119 hasConceptScore W4313550119C149923435 @default.
• W4313550119 hasConceptScore W4313550119C19165224 @default.
• W4313550119 hasConceptScore W4313550119C2780084366 @default.
• W4313550119 hasConceptScore W4313550119C2908647359 @default.
• W4313550119 hasConceptScore W4313550119C512399662 @default.
• W4313550119 hasConceptScore W4313550119C535046627 @default.
• W4313550119 hasConceptScore W4313550119C71924100 @default.
• W4313550119 hasConceptScore W4313550119C74909509 @default.
• W4313550119 hasConceptScore W4313550119C99454951 @default.
• W4313550119 hasFunder F4320311413 @default.
• W4313550119 hasIssue "1" @default.
• W4313550119 hasLocation W43135501191 @default.
• W4313550119 hasLocation W43135501192 @default.
• W4313550119 hasLocation W43135501193 @default.
• W4313550119 hasOpenAccess W4313550119 @default.
• W4313550119 hasPrimaryLocation W43135501191 @default.
• W4313550119 hasRelatedWork W1984201488 @default.
• W4313550119 hasRelatedWork W2030973322 @default.
• W4313550119 hasRelatedWork W2049217636 @default.
• W4313550119 hasRelatedWork W2099510828 @default.
• W4313550119 hasRelatedWork W2106404923 @default.
• W4313550119 hasRelatedWork W2121684991 @default.
• W4313550119 hasRelatedWork W2519550798 @default.
• W4313550119 hasRelatedWork W393588758 @default.
• W4313550119 hasRelatedWork W4311068385 @default.
• W4313550119 hasRelatedWork W4315849358 @default.
• W4313550119 hasVolume "2" @default.
• W4313550119 isParatext "false" @default.

• next